Can I Take Omega-3 (EPA/DHA) with Rezdiffra (Resmetirom)?

Rezdiffra (resmetirom) is a thyroid hormone receptor-beta (THR-beta) agonist tablet approved by the FDA for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH/NAFLD) with moderate to advanced liver fibrosis (stage F2-F3), used alongside diet and exercise. Omega-3 fatty acids, meaning eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are widely used over-the-counter supplements, and prescription-strength EPA (icosapent ethyl) is FDA-approved for severe hypertriglyceridemia and, in some patients, for cardiovascular risk reduction. These are two distinct product categories, and this page addresses whether taking them together is safe, not whether omega-3 treats liver disease on its own.

The direct answer: no pharmacokinetic drug-supplement interaction between resmetirom and omega-3 fatty acids is described in the Rezdiffra prescribing information, and the two substances are cleared through different metabolic routes, so a blood-level conflict is not expected. The more relevant issue is pharmacodynamic overlap, both agents lower triglycerides, and a separate bleeding consideration for patients also taking an anticoagulant or antiplatelet drug at higher omega-3 doses. This is general information, not individualized dosing advice, and anyone on both products should confirm their specific regimen with the prescriber managing their MASH treatment.

The question that actually matters here

For most readers, the useful question is not "does omega-3 block resmetirom" (there is no documented mechanism for that) but "does combining them change what needs to be monitored." The answer is yes for two specific groups: patients on anticoagulant or antiplatelet therapy, and patients already near the lower end of normal triglycerides or on additional lipid-lowering drugs. For everyone else, the combination looks like two agents working on the same lab value (triglycerides) through different pathways, which is generally a reason for more monitoring, not less use.

What Rezdiffra does and why omega-3 comes up

Resmetirom selectively activates THR-beta, a receptor concentrated in liver cells. Activation is understood to increase hepatic fatty acid oxidation and reduce liver fat and certain atherogenic lipoproteins, which is the basis of its approval for MASH with fibrosis. According to the FDA-approved label, resmetirom is metabolized primarily by the liver enzyme CYP2C8, and strong CYP2C8 inhibitors (such as gemfibrozil) require a dose adjustment (FDA label).

Omega-3 fatty acids are commonly used by patients with fatty liver disease before they are ever prescribed resmetirom, so the overlap in practice is frequent rather than incidental. Trials of purified EPA and DHA have reported reductions in liver fat and triglycerides in patients with fatty liver disease, and prescription omega-3 formulations are FDA-approved for severe hypertriglyceridemia (triglycerides at or above 500 mg/dL). The magnitude of liver-fat or triglyceride reduction reported in specific trials (for example, the WELCOME and REDUCE-IT studies referenced in earlier versions of this content) should be checked against the primary published papers before being cited with a specific percentage; those exact figures require verification and are not repeated here as precise numbers.

Is there a pharmacokinetic interaction?

Resmetirom is absorbed orally and metabolized mainly by CYP2C8, with a minor contribution from CYP3A4, per its FDA label. Omega-3 fatty acids at typical supplemental doses (roughly 1 to 4 g/day) are not established inhibitors or inducers of CYP2C8 or CYP3A4; they are cleared largely through beta-oxidation and incorporation into cell membranes rather than through cytochrome P450 pathways. This is a pharmacologically plausible basis for saying a clinically meaningful pharmacokinetic interaction is unlikely, but it is not the same as a dedicated interaction study proving the absence of one. No such dedicated pharmacokinetic interaction trial between resmetirom and omega-3 appears to exist in the public record reviewed for this article.

The Rezdiffra label lists specific precautions around strong CYP2C8 inhibitors and dual CYP2C8/CYP3A4 inhibitors. It does not list omega-3 supplements as a contraindication or a required dose adjustment (FDA label). Absence of a listed interaction is meaningfully different from a confirmed negative study; it typically reflects that omega-3 was not part of formal interaction testing, not that testing ruled out an effect.

Both resmetirom and long-chain omega-3 fatty acids bind extensively to plasma proteins. In principle, competition for albumin binding could raise free concentrations of one or both compounds. In practice, protein-binding displacement is rarely clinically significant for highly protein-bound drugs because the body's distribution volume adjusts, and this remains a theoretical consideration rather than a reported clinical problem for this pair.

Pharmacodynamic overlap: triglycerides and bleeding

The interaction that matters most in practice is not pharmacokinetic but additive drug effect.

Triglycerides. Resmetirom reduces triglycerides as part of its lipid effects, and prescription-strength EPA (icosapent ethyl) and other omega-3 formulations are separately known to lower triglycerides, sometimes substantially, in patients with elevated baseline levels. Taking both together is plausible to produce a larger combined triglyceride reduction than either agent alone, though the exact combined magnitude has not been established in a dedicated trial of resmetirom plus omega-3 and should not be assumed from adding two separately reported percentages. For most patients with baseline hypertriglyceridemia, an additive triglyceride-lowering effect is a benefit, not a risk, but it is a reason to recheck a fasting lipid panel after starting the combination rather than assuming stability.

Bleeding risk. Omega-3 fatty acids at doses above roughly 3 g/day have a modest, established antiplatelet effect through reduced thromboxane A2 production. Resmetirom itself has no documented antiplatelet or anticoagulant activity. The bleeding concern therefore applies to patients who are also taking warfarin, aspirin, clopidogrel, or a direct oral anticoagulant, not to the resmetirom-omega-3 combination by itself. For these patients, closer monitoring of INR (on warfarin) or clinical bleeding symptoms is a reasonable precaution when high-dose omega-3 is added or increased, independent of resmetirom.

Thyroid hormone. Because resmetirom works through a thyroid hormone receptor, patients sometimes ask whether omega-3 affects thyroid levels. Omega-3 fatty acids are not established to affect TSH, T3, or T4 levels, and resmetirom's action is receptor-selective in the liver rather than a systemic thyroid hormone effect. This particular worry is not supported by the available pharmacology.

Evidence-status interaction assessment

A pharmacist or prescriber reviewing this combination should specifically verify: the patient's current omega-3 dose and formulation (over-the-counter fish oil versus prescription icosapent ethyl), any concurrent anticoagulant or antiplatelet medication, baseline and follow-up triglyceride and hepatic enzyme values, and whether any other CYP2C8 inhibitor (such as gemfibrozil) is also in the regimen.

Monitoring when taking both

The Rezdiffra label recommends checking hepatic function before starting treatment and periodically thereafter. A reasonable approach when omega-3 is also being taken is to add a fasting lipid panel to that same monitoring schedule so the combined triglyceride effect is visible, and to check INR more often in the weeks after starting or increasing omega-3 in a patient already on warfarin. Consider reassessing the omega-3 dose if triglycerides fall unusually low, if unexplained bruising or bleeding develops, or if gastrointestinal side effects (loose stools, nausea) become bothersome, since both resmetirom and omega-3 can independently cause gastrointestinal symptoms and the two may add together.

Dose and timing

Resmetirom is taken once daily with food, per its label. There is no established pharmacokinetic reason to separate it in time from an omega-3 capsule, and taking both at the same meal is a reasonable, commonly used approach. Whether a fat-containing omega-3 capsule meaningfully changes resmetirom absorption beyond what a normal meal already provides has not been studied in a dedicated food-effect analysis and should not be assumed as a benefit.

Special populations

Patients on anticoagulants or antiplatelet drugs. This is the group where the combination genuinely changes monitoring needs. Warfarin is partly metabolized through CYP-dependent pathways, and while no clinical interaction between resmetirom and warfarin has been reported, adding high-dose omega-3 introduces a second variable affecting bleeding risk. Closer INR monitoring after starting or changing omega-3 dose is a reasonable precaution regardless of resmetirom.

Patients with severe hypertriglyceridemia. For patients with triglycerides at or above 500 mg/dL, prescription omega-3 is often already part of guideline-directed therapy independent of MASH treatment. Adding resmetirom in this population is plausible to provide additional benefit, but a fibrate should be added only with caution, since gemfibrozil is a strong CYP2C8 inhibitor that requires a resmetirom dose adjustment per the label.

Patients with fish or shellfish allergy. Highly purified pharmaceutical-grade EPA/DHA products generally contain minimal fish protein, and many patients with fish allergy tolerate them, but this decision should be made with an allergist or prescriber rather than inferred from this article. Algal-derived, DHA-dominant omega-3 is an alternative that avoids fish-sourced material.

What is established, what is plausible, and what is not established

Established: Resmetirom is metabolized mainly by CYP2C8; the FDA label does not list omega-3 as a contraindicated or dose-adjusted co-administration; omega-3 at doses above roughly 3 g/day has a modest antiplatelet effect; resmetirom carries its own gastrointestinal side effect profile independent of omega-3.

Plausible but unproven: That combining resmetirom and omega-3 produces a meaningfully larger triglyceride reduction than either alone, in a specific measurable amount; that albumin-binding competition has any clinically detectable effect on free drug levels for either agent.

Not established: Any specific percentage figure for combined triglyceride or liver-fat reduction when resmetirom and omega-3 are used together; a direct pharmacokinetic interaction study of the two agents together, which does not appear to exist in the public record reviewed here.

If a triglyceride reading, bleeding event, or unexplained lab change occurs while on this combination, that warrants a call to the prescribing clinician rather than a change made independently. Sudden right-upper-quadrant pain, jaundice, unusual bruising, or dark urine should prompt urgent evaluation regardless of supplement use.